Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2021.09.02

Sai Life Sciences’ API Manufacturing unit receives ‘CII Excellent Energy Efficient Unit’ award

Sai Life Sciences’ API Manufacturing unit receives ‘CII Excellent Energy Efficient Unit’ award

Sai Life Sciences, a global CRO & CDMO offering sustainable solutions to pharmaceutical companies through strategic partnerships and integrated drug discovery and development services, has been awarded with ‘Excellent Energy Efficient Unit’ in the general category at CII’s 22nd National Energy Management Awards. This is the second consecutive year that Sai Life Sciences’ Bidar API manufacturing unit has been awarded by CII for its energy management.  

Congratulating the team, Krishna Kanumuri, CEO & Managing Director said, ‘’The consistency of our performance in energy conservation and sustainability parameters in the past two years speaks volumes on the commitment of our engineers and utility managers who are relentless in their focus and consistently come up with innovative solutions to take us closer to our sustainable development goals.”

The 22nd edition of National Award for Excellence in Energy Management is a flagship event of Confederation of Indian Industries (CII) with the objective to recognize and award excellence in energy management and facilitate the sharing of information on best practices and technologies. CII’s National Energy Award is the best platform for the organizations that have made outstanding contributions in energy efficiency to showcase their efforts and achievements.

The Bidar API manufacturing facility of Sai Life Sciences has been on a path of significant expansion with its production capacity growing from 200KL in 2017 to 450KL today and on course to be 600KL in 2022. Along the way it has ensured a steadfast commitment to safer, compliant and sustainable manufacturing practices.

Key energy conservation performance indicators of the site FY21

The following improvements in the site’s energy performance were achieved while sustaining a significant increase in the overall production of finished goods YoY:

Energy cost reduction
- 10% drop in thermal cost
- 5% drop in electrical cost

Energy consumption reduction
- 7.7% drop in thermal consumption
- 5.5% drop in electrical consumption

Specific Energy Consumption (SEC)
- 19% reduced w.r.t MTOE/ Ton of FG

Energy conservation projects (energy saving)
- FY20: 0.40 million kWh units/annum (Rs.3.03 million/ year)
- FY21: 1.33 million kWh units/annum (Rs.9.64 million/ year)

CO2 Emissions
- FY20: 338 Tons CO2 / ton FG
- FY21: 210 Tons CO2 / ton FG (37 % drop compared to FY20)

Renewable Energy Adoption
- FY 2020: 21%
- FY 2021: 53%

The recognition of Bidar manufacturing unit has followed the recent milestone of Sai Life Sciences becoming a signatory of United Nations Global Compact and receiving a 5-star rating for excellence in EHS practices at the 13th edition of the Confederation of Indian Industry’s (CII-SR) EHS Excellence Awards.

Share article

More News

2025.09.05

Reviving Kudikunta Lake: Bringing nature and community closer together

As part of its Corporate Social Responsibility initiative, Sai Life Sciences has taken up the development of Kudikunta Lake in Hyderabad, reinforcing its commitment to sustainability and community well-being. The Kudikunta Lake initiative marks a significant step in restoring one of Hyderabad’s key lakes and advancing the cause of sustainable urban living. The company has […]
Read more

2025.09.05

From injections to pills: oral peptides set to transform drug development

In a recent article published in Drug Target Review, Dr Santosh Kulkarni highlights the shift from injections to pills. He writes about how oral peptide therapeutics are overcoming the long-standing challenge of poor bioavailability—bringing us closer to patient-friendly medicines without compromising efficacy. The article highlights the booming peptide drug market and the scientific advances—from chemical […]
Read more

2025.08.28

Sai Life Sciences completes Phase II of Production Block 11 at Bidar site, India, expands capacity to 700 KL

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the completion of Phase II of its new Production Block (PB-11) at the company’s flagship API manufacturing facility in Bidar, India (Unit IV). The Phase I of PB-11, with a capacity of 110 KL, was inaugurated […]
Read more

2025.08.20

Sai Life Sciences secures SBTi validation for near-term climate targets

Sai Life Sciences Limited, an innovator focused Contract Research, Development, and Manufacturing Organization (CRDMO), announced that its near-term targets to cut greenhouse gas (GHG) emissions have been validated by the Science Based Targets initiative (SBTi)—a corporate climate action organization that enables companies and financial institutions worldwide to play their part in combating the climate crisis. […]
Read more

2025.08.20

Sai Life Sciences featured in Drug Discovery & Development on trends shaping drug discovery

Sai Life Sciences was recently featured in Drug Discovery & Development, where Dr Maneesh Pingle, Executive Vice President and Head of Discovery Services, shared insights on the emerging trends in pharma sector. A key focus was the impact of GLP 1 agonists in accelerating peptide drug discovery. Dr. Pingle explained how the success of these […]
Read more